EWING, N.J.--(BUSINESS WIRE)--Antares Pharma, Inc. (NASDAQ:ATRS) today announced that a meeting was held with the U.S. Food and Drug Administration (FDA) to discuss a registration study for the VIBEX ...
IRVINE, Dec. 27, 2025 (GLOBE NEWSWIRE) -- Disclaimer: This article is for informational purposes only and does not constitute medical advice. Testosterone replacement therapy requires evaluation and ...
EWING, N.J., May 16, 2017 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS) announced that data from its Phase 3 study of the pharmacokinetics and safety of subcutaneous testosterone enanthate ...
* Antares Pharma Inc - submitted a new drug application (nda) to U.S. Food And Drug Administration (FDA) for quickshot testosterone Sign up here. * Antares Pharma Inc - quickshot testosterone auto ...
Independent analysis examines Fridays' published TRT program structure, delivery format options, and what clinical research indicates for men evaluating prescription testosterone pathways heading into ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback